Nancy Van Prooyen, PhD
About Nancy Van Prooyen, PhD
Nancy Van Prooyen, PhD, is the Associate Director at Bristol Myers Squibb in Redwood City, California, with extensive experience in immuno-oncology and autoimmune diseases.
Current Position
Nancy Van Prooyen, PhD, is currently serving as an Associate Director at Bristol Myers Squibb in Redwood City, California, United States. In her role at Bristol Myers Squibb, she is likely involved in overseeing advanced research and development projects, with a particular focus on oncology and immuno-oncology.
Previous Experience
Before her current role, Nancy Van Prooyen held the position of Senior Principal Scientist at Bristol Myers Squibb from 2021 to 2022. Her prior experience also includes working as a Senior Scientist in Translation Research in Immuno-Oncology and Autoimmunity at Nektar Therapeutics from 2019 to 2021, and as a Research Scientist in Autoimmune Diseases at Theravance Biopharma US, Inc. from 2018 to 2019. Additionally, she served as a Scientist in Immuno-Oncology at FLX Bio, Inc. from 2016 to 2017.
Educational Background
Nancy Van Prooyen achieved her PhD from The Johns Hopkins University in Cell, Molecular, Developmental Biology, and Biophysics, studying from 2004 to 2010. She also holds a BA in Biochemistry and Molecular Biology from Reed College, which she earned between 1999 and 2003. Furthermore, she has a Regulatory Affairs Certificate in Pharmaceuticals from the Regulatory Affairs Professional Society obtained in 2014.
Research and Publications
Nancy Van Prooyen has co-authored multiple peer-reviewed scientific publications in the field of immuno-oncology. She has also presented her research findings at international conferences, including the American Association for Cancer Research (AACR) Annual Meeting. Her work primarily focuses on developing and implementing clinical biomarker strategies for immuno-oncology trials.
Professional Contributions
Throughout her career, Nancy Van Prooyen has mentored junior scientists and postdoctoral fellows, fostering their professional growth. She has led cross-functional teams in the development of novel therapeutic candidates targeting immune checkpoints and collaborated with external academic and industry partners to advance translational research projects. Additionally, she has served as a reviewer for scientific journals in immunology and oncology and has received recognition through industry awards and honors for her contributions to the field.